Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma

Summary

This phase II trial studies the side effects and best dose of propranolol when administered concurrently with SOC neoadjuvant CRT in patients with esophageal carcinoma, with a safety lead-in and dose expansion cohort. Patients who are already on β-blockers will receive standard of care CRT, or definitive chemotherapy or chemotherapy-immunotherapy and will be considered separately as a single arm prospective cohort

Timeline

Start

2021-04-01

Primary completion

2029-04-01

Completion

2029-04-01

Drugs

Indications